Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TK2 | O00142 | 6/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8707821 | 0.89 | TK1 (0.64) | TK1HPGDTK2MAPK1 | |
| SCHEMBL1833366 | 0.82 | TK1 (0.46) | TK1MAPK1UPP1CYP2C9CYP2C19 | |
| SCHEMBL9391820 | 0.78 | HPGD (0.60) | TK1HPGDTK2MAPK1 | |
| SCHEMBL13723199 | 0.78 | TYMP (0.45) | TK1HPGDTK2MAPK1 | |
| SCHEMBL17013802 | 0.78 | TK1 (0.59) | TK1HPGDTK2MAPK1 | |
| SCHEMBL4088248 | 0.76 | UPP1 (0.57) | HPGDMAPK1UPP1 | |
| SCHEMBL13402919 | 0.76 | TYMP (0.54) | TK1HPGDTK2MAPK1 | |
| SCHEMBL13724173 | 0.76 | MEN1 (0.55) | TK1HPGDTK2MAPK1 | |
| SCHEMBL6722443 | 0.75 | HPGD (0.68) | TK1HPGDTK2MAPK1UPP1 | |
| SCHEMBL10458144 | 0.75 | TK1 (0.57) | TK1TK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| EP-2001488-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | Alt Solutions, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007106561-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | ALT SOLUTIONS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-4916121-A | PHOSPHORYLASE INHIBITOR | TEIJIN LIMITED (JP) | 1990-04-10 | — | — | US | disclosed |
| EP-0202056-B1 | ANTITUMOR AGENT | TEIJIN LIMITED (JP) | 1989-08-30 | — | — | EP | disclosed |
| EP-0202056-A1 | Antitumor agent | TEIJIN LIMITED (JP) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | TERT, POLRMT, RNASE1 | TK1 16/4885HPGD 815/4885TK2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.